CAK—Cyclin-Dependent Activating Kinase: A Key Kinase in Cell Cycle Control and a Target for Drugs?

Graziano Lolli, L.N. Johnson

Cell Cycle · 2005 · 195 citations · 0 references

DOIFull text

Open access

Concepts

TL;DR

Cyclin‑dependent kinase activating kinase (CAK) phosphorylates CDK1/2/4/6, is part of TFIIH, and is essential for cell‑cycle progression, making CDK7 a potential cancer target despite toxicity concerns from its ubiquitous transcriptional role. This review examines CAK’s roles in biology and assesses CDK7 as a pharmacological target. We analyze the recently solved CDK7 structure to guide the design of inhibitors with selective specificity for different CDKs.

Abstract

The Cyclin-dependent kinase (CDK) Activating Kinase (CAK) is responsible for the activating phosphorylation of CDK1, CDK2, CDK4 and CDK6 and regulation of the cell cycle. The kinase is composed of three subunits: CDK7, Cyclin H and MAT1 (ménage a trois). Together with six other subunits, CAK is also part of the general transcription factor TFIIH where it is involved in promoter clearance and progression of transcription from the pre-initiation to the initiation stage. CAK is required for cell cycle progression, which suggests that CDK7 could be a target for cancer therapy. However its role in transcription and its ubiquitous presence raise sensible concerns about possible toxicity of its inhibitors. The recently determined structure of CDK7 allows the design of inhibitors with differential specificity for the different CDKs. We review the role of CAK in different biological processes and evaluate the biological evidence for CDK7 as a possible pharmacological target.